Gesher Acquisition (GSHR) EBITDA (2025 - 2026)

Gesher Acquisition (GSHR) posted quarterly EBITDA of -$498767.0 for Q4 2025, down 63.14% quarter-over-quarter from -$305728.0 in Q3 2025.

Gesher Acquisition (GSHR) EBITDA (2025 - 2026) Analysis & Trends

Gesher Acquisition (GSHR) has reported EBITDA for 1 consecutive years, with -$498767.0 the latest figure, recorded in Q4 2025.

In Q4 2025, EBITDA changed N/A year-over-year to -$498767.0; the TTM figure through Dec 2025 stood at -$1.1 million (changed N/A YoY), while the FY2025 annual figure was -$1.1 million, down 6934.08% from the prior year.
EBITDA retreated to -$498767.0 in Q4 2025 per GSHR's latest filing, from -$305728.0 in the prior quarter.
Across five years, EBITDA topped out at -$84174.0 in Q1 2025 and bottomed at -$498767.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Launch Two Acquisition	557.86 Mn	557.86 Mn	-	-194,528.00
2	Drugs Made In America Acquisition	507.00 Mn	507.00 Mn	-	-112,227.00
3	Cantor Equity Partners IV	467.55 Mn	467.55 Mn	-	-174,182.00
4	GP-Act III Acquisition	401.06 Mn	401.06 Mn	-	-1.47 Mn
5	Aldel Financial	397.49 Mn	397.49 Mn	-	-115,742.00
6	Gores Holdings X	381.05 Mn	380.85 Mn	-	-1.35 Mn
7	Agriculture & Natural Solutions Acquisition	377.29 Mn	377.04 Mn	-	-
8	Blue Water Acquisition Corp. III	342.12 Mn	342.08 Mn	-	-197,949.00
9	Berto Acquisition	313.96 Mn	313.81 Mn	-	-1.62 Mn
10	Gesher Acquisition	157.32 Mn	157.32 Mn	-	-374,532.00

Download Data